Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 8/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663040 | 0.90 | PPARA (0.37) | PPARACYP1A2CYP3A4PPARGALDH1A1 | |
| SCHEMBL5663030 | 0.81 | — | — | |
| SCHEMBL5660995 | 0.78 | MCL1 (0.47) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5661012 | 0.77 | PPARA (0.42) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5663198 | 0.77 | PPARA (0.54) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5660099 | 0.76 | PPARA (0.43) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5662960 | 0.75 | MTNR1A (0.43) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5661653 | 0.73 | PPARG (0.55) | PPARAFBP1PPARGGRM2 | |
| SCHEMBL5661816 | 0.72 | PPARA (0.49) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5660646 | 0.72 | PPARA (0.48) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | claimed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARA 251/4885ABCB11 90/4885CYP1A2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.